Emergent BioSolutions
EBS
#6766
Rank
โ‚ฌ0.54 B
Marketcap
10,22ย โ‚ฌ
Share price
-1.24%
Change (1 day)
18.22%
Change (1 year)

Emergent BioSolutions (EBS) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚ฌ0.75 Billion

According to Emergent BioSolutions 's latest financial reports the company's total liabilities are โ‚ฌ0.75 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ0.87 B-17.93%
2023-12-31โ‚ฌ1.06 B-35.96%
2022-12-31โ‚ฌ1.65 B39.49%
2021-12-31โ‚ฌ1.18 B1.8%
2020-12-31โ‚ฌ1.16 B5.59%
2019-12-31โ‚ฌ1.10 B3.82%
2018-12-31โ‚ฌ1.06 B709.37%
2017-12-31โ‚ฌ0.13 B-62.98%
2016-12-31โ‚ฌ0.35 B2.97%
2015-12-31โ‚ฌ0.34 B8.92%
2014-12-31โ‚ฌ0.31 B218.43%
2013-12-31โ‚ฌ99.53 M7.83%
2012-12-31โ‚ฌ92.3 M-7.88%
2011-12-31โ‚ฌ0.10 B5.15%
2010-12-31โ‚ฌ95.29 M35.35%
2009-12-31โ‚ฌ70.4 M7.65%
2008-12-31โ‚ฌ65.4 M-6.69%
2007-12-31โ‚ฌ70.09 M-7.31%
2006-12-31โ‚ฌ75.62 M120.67%
2005-12-31โ‚ฌ34.26 M0.82%
2004-12-31โ‚ฌ33.98 M
2002-12-31โ‚ฌ17.82 M-72.72%
2001-12-31โ‚ฌ65.35 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Merck
MRK
โ‚ฌ66.66 B 8,737.68%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
โ‚ฌ24.15 M-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚ฌ52.62 B 6,876.03%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
โ‚ฌ43 M-94.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ99.29 B 13,062.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ27.99 B 3,611.10%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
โ‚ฌ3.17 M-99.58%๐Ÿ‡บ๐Ÿ‡ธ USA